Chemopreventive potential of natural compounds in head and neck cancer

Nutrition and Cancer

Volumn 62, Issue 7, 2010, Pages 973-987

  Rahman, Mohammad Aminur ^a   Amin, A R M Ruhul ^a   Shin, Dong M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALPHA2A INTERFERON; ATORVASTATIN; BETA CAROTENE; BEVACIZUMAB; BORTEZOMIB; CELECOXIB; CETUXIMAB; CISPLATIN; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; ERLOTINIB; GEFITINIB; GENISTEIN; GREEN TEA EXTRACT; ISOTRETINOIN; LUTEOLIN; N 4 (HYDROXYCARBOPHENYL)RETINAMIDE; NATURAL PRODUCT; PANITUMUMAB; RETINOID DERIVATIVE; RETINOL; SORAFENIB; SULINDAC; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLADDER TUMOR; BREAST CANCER; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESEARCH; DRUG TARGETING; DRUG WITHDRAWAL; ESOPHAGUS TUMOR; FAMILIAL POLYPOSIS; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; INTESTINE TUMOR; LARYNX TUMOR; LEUKOPLAKIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; PRECANCER; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TONGUE TUMOR; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOMA, SQUAMOUS CELL; CATECHIN; CURCUMIN; CYCLOOXYGENASE 2 INHIBITORS; HEAD AND NECK NEOPLASMS; HUMANS; NF-KAPPA B; RECEPTOR, EPIDERMAL GROWTH FACTOR; STILBENES; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77958010311     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635581.2010.509538     Document Type: Review

References (214)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al.: Cancer statistics, 2009. CA Cancer J Clin 59, 225-249, 2009.
2. Haddad RI and Shin DM: Recent advances in head and neck cancer. N Engl J Med 359, 1143-1154, 2008.
3. Tsao AS, Kim ES, and Hong WK: Chemoprevention of cancer. CA Cancer J Clin 54, 150-180, 2004.
4. Khuri FR, Kim ES, Lee JJ, Winn RJ, Benner SE, et al.: The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 10, 823-829, 2001.
5. Abbruzzese JL and Lippman SM: The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 6, 321-326, 2004.
6. Khuri FR and Shin DM: Head and neck cancer chemoprevention gets a shot in the arm. J Clin Oncol 26, 345-347, 2008.
7. Amin AR, Kucuk O, Khuri FR, and Shin DM: Perspectives for cancer prevention with natural compounds. J Clin Oncol 27, 2712-2725, 2009.
8. Reddy L, Odhav B, and Bhoola KD: Natural products for cancer prevention: a global perspective. Pharmacol Ther 99, 1-13, 2003.
9. Block G, Patterson B, and Subar A: Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18, 1-29, 1992.
10. Benetou V, Orfanos P, Lagiou P, Trichopoulos D, Boffetta P, et al.: Vegetables and fruits in relation to cancer risk: evidence from the Greek EPIC cohort study. Cancer Epidemiol Biomarkers Prev 17, 387-392, 2008.
11. Glade MJ: Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997. Nutrition 15, 523-526, 1999.
12. Prevention of cancer in the next millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 59, 4743-4758, 1999.
13. Greenwald P: Cancer chemoprevention. BMJ 324, 714-718, 2002.
14. Vokes EE, Weichselbaum RR, Lippman SM, and Hong WK: Head and neck cancer. N Engl J Med 328, 184-194, 1993.
15. Gao X, Fisher SG, Mohideen N, and Emami B: Second primary cancers in patients with laryngeal cancer: a population-based study. Int J Radiat Oncol Biol Phys 56, 427-435, 2003.
16. Hunter KD, Parkinson EK, and Harrison PR: Profiling early head and neck cancer. Nat Rev Cancer 5, 127-135, 2005.
17. O'Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, et al.: Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8, 314-346, 2002.
18. Curfman GD, Morrissey S, and Drazen JM: Retraction: Sudbo J et al. DNA content as a prognostic marker in patients with oral leukoplakia. N Engl J Med 344, 1270-1278, 2001 and
19. Sudbo J et al. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 350, 1405-1413, 2004.
20. N Engl J Med 355, 1927, 2006.
21. Wolbach SB and Howe PR: Tissue changes following deprivation of fatsoluble a vitamin. J Exp Med 42, 753-777, 1925.
22. Sporn MB, Dunlop NM, Newton DL, and Smith JM: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35, 1332-1338, 1976.
23. Lippman SM, Lee JJ, and Sabichi AL: Cancer chemoprevention: progress and promise. J Natl Cancer Inst 90, 1514-1528, 1998.
24. Hong WK, Spitz MR, and Lippman SM: Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets. J Clin Oncol 18, 9S-18S, 2000.
25. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, et al.: 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315, 1501-1505, 1986.
26. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, et al.: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323, 795-801, 1990.
27. Stich HF, Rosin MP, Hornby AP, Mathew B, Sankaranarayanan R, et al.: Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 42, 195-199, 1988.
28. Lippman SM, Batsakis JG, Toth BB, Weber RS, Lee JJ, et al.: Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 328, 15-20, 1993.
29. Papadimitrakopoulou VA, Hong WK, Lee JS, Martin JW, Lee JJ, et al.: Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 89, 257-258, 1997.
30. Benner SE, Pajak TF, Lippman SM, Earley C, and Hong WK: Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 86, 140-141, 1994.
31. Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, et al.: Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19, 3010-3017, 2001.
32. Seixas-Silva JA Jr, Richards T, Khuri FR, Wieand HS, Kim E, et al.: Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg 131, 304-307, 2005.
33. Khuri FR, Lee JJ, Lippman SM, Kim ES, Cooper JS, et al.: Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 98, 441-450, 2006.
34. Papadimitrakopoulou VA, Lee JJ, William WN Jr, Martin JW, Thomas M, et al.: Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27, 599-604, 2009.
35. Stich HF, Hornby AP, Mathew B, Sankaranarayanan R, and Nair MK: Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 40, 93-101, 1988.
36. DeLaney TF, Afridi N, Taghian AG, Sanders DA, Fuleihan NS, et al.: 13-cis-retinoic acid with alpha-2a-interferon enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro. Cancer Res 56, 2277-2280, 1996.
37. Lingen MW, Polverini PJ, and Bouck NP: Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 58, 5551-5558, 1998.
38. Lindner DJ and Borden EC: Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptornegative human tumor cell lines in vivo and in vitro. J Interferon Cytokine Res 17, 681-693, 1997.
39. Papadimitrakopoulou VA, Clayman GL, Shin DM, Myers JN, Gillenwater AM, et al.: Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 125, 1083-1089, 1999.
40. Rotmensz N, De Palo G, Formelli F, Costa A, Marubini E, et al.: Longterm tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer 27, 1127-1131, 1991.
41. Han J, Jiao L, Lu Y, Sun Z, Gu QM, et al.: Evaluation of N-4-(hydroxycarbophenyl) retinamide as a cancer prevention agent and as a cancer chemotherapeutic agent. In Vivo 4, 153-160, 1990.
42. Chiesa F, Tradati N, Marazza M, Rossi N, Boracchi P, et al.: Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem Suppl 17 F, 255-261, 1993.
43. Lotan R: Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst 87, 1655-1657, 1995.
44. Oridate N, Lotan D, Xu XC, Hong WK, and Lotan R: Differential induction of apoptosis byall-trans-retinoic acid and N-(4-hydroxyphenyl) retinamide in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2, 855-863, 1996.
45. Papadimitrakopoulou VA, William WN Jr, Dannenberg AJ, Lippman SM, Lee JJ, et al.: Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 14, 2095-2101, 2008.
46. Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, et al.: Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila Pa) 2, 931-941, 2009.
47. Fisher B, Powles TJ, and Pritchard KJ: Tamoxifen for the prevention of breast cancer. Eur J Cancer 36, 142-150, 2000.
48. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342, 1946-1952, 2000.
49. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, et al.: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90, 824-832, 1998.
50. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, et al.: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62, 7350-7356, 2002.
51. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, et al.: Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25, 2164-2170, 2007.
52. Citri A and Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7, 505-516, 2006.
53. Matta A and Ralhan R: Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol 1, 6, 2009.
54. Kalyankrishna S and Grandis JR: Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24, 2666-2672, 2006.
55. Bernier J, Bentzen SM, and Vermorken JB: Molecular therapy in head and neck oncology. Nat Rev Clin Oncol 6, 266-277, 2009.
56. Shin DM, Ro JY, Hong WK, and Hittelman WN: Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54, 3153-3159, 1994.
57. Nozawa H, Tadakuma T, Ono T, Sato M, Hiroi S, et al.: Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci 97, 1115-1124, 2006.
58. Amin AR, Khuri FR, Chen ZG, and Shin DM: Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and epigallocatechin-3-gallate: the role of p53-dependent inhibition of nuclear factor-kappaB. Cancer Prev Res (Phila Pa) 2, 538-545, 2009.
59. Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, et al.: PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene 28, 2348-2357, 2009.
60. Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, et al.: Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 15, 2361-2372, 2009.
61. Zhang X, Zhang H, Tighiouart M, Lee JE, Shin HJ, et al.: Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3- gallate and EGFR tyrosine kinase inhibitor. Int J Cancer 123, 1005-1014, 2008.
62. Choe MS, Zhang X, Shin HJ, Shin DM, and Chen ZG: Interaction between epidermal growth factor receptor-and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 4, 1448-1455, 2005.
63. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, et al.: Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 11, 6261-6269, 2005.
64. Grandis JR and Tweardy DJ: Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 53, 3579-3584, 1993.
65. Cohen EE, Davis DW, Karrison TG, Seiwert TY, Wong SJ, et al.: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 10, 247-257, 2009.
66. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, et al.: Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11, 21-28, 2010.
67. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, et al.: Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2, 544-551, 2001.
68. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, and Boyle JO: Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck 24, 792-799, 2002.
69. Jacoby RF, Seibert K, Cole CE, Kelloff G, and Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 60, 5040-5044, 2000.
70. Fischer SM, Lo HH, Gordon GB, Seibert K, Kelloff G, et al.: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 25, 231-240, 1999.
71. Kawamori T, Rao CV, Seibert K, and Reddy BS: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 58, 409-412, 1998.
72. Buttar NS, Wang KK, Leontovich O, Westcott JY, Pacifico RJ, et al.: Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122, 1101-1112, 2002.
73. Nishimura G, Yanoma S, Mizuno H, Kawakami K, and Tsukuda M: A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn J Cancer Res 90, 1152-1162, 1999.
74. Liu XH, Yao S, Kirschenbaum A, and Levine AC: NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis, and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58, 4245-4249, 1998.
75. Hara A, Yoshimi N, Niwa M, Ino N, and Mori H: Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res 88, 600-604, 1997.
76. Hirsch FR and Lippman SM: Advances in the biology of lung cancer chemoprevention. J Clin Oncol 23, 3186-3197, 2005.
77. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, et al.: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164, 361-370, 2000.
78. Shishodia S and Aggarwal BB: Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2, and matrix metalloproteinase-9. Cancer Res 64, 5004-5012, 2004.
79. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, et al.: Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 57, 2890-2895, 1997.
80. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, et al.: Retinoids suppress phorbol ester-mediated induction of cyclooxygenase-2. Cancer Res 57, 1081-1085, 1997.
81. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, et al.: Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60, 1326-1331, 2000. (Pubitemid 30152002)
82. Bode AM and Dong Z: Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4, 793-805, 2004.
83. Shin DM, Charuruks N, Lippman SM, Lee JJ, Ro JY, et al.: p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. Cancer Epidemiol Biomarkers Prev 10, 603-609, 2001.
84. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, and Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70, 937-948, 1992.
85. Eyfjord JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ogmundsdottir HM, et al.: p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55, 646-651, 1995.
86. Sood AK, Skilling JS, and Buller RE: Ovarian cancer genomic instability correlates with p53 frameshift mutations. Cancer Res 57, 1047-1049, 1997.
87. Uchida T, Wada C, Wang C, Egawa S, Ohtani H, et al.: Genomic instability of microsatellite repeats and mutations of H-, K-, and N-ras, and p53 genes in renal cell carcinoma. Cancer Res 54, 3682-3685, 1994.
88. Shin DM, Xu XC, Lippman SM, Lee JJ, Lee JS, et al.: Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin Cancer Res 3, 875-880, 1997.
89. Lippman SM, Shin DM, Lee JJ, Batsakis JG, Lotan R, et al.: p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 55, 16-19, 1995.
90. Gilmore TD: Introduction to NF-kappaB: players, pathways, perspectives. Oncogene 25, 6680-6684, 2006.
91. Brasier AR: The NF-kappaB regulatory network. Cardiovasc Toxicol 6, 111-130, 2006.
92. Perkins ND: Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 8, 49-62, 2007.
93. Tergaonkar V: NFkappaB pathway: a good signaling paradigm and therapeutic target. Int J Biochem Cell Biol 38, 1647-1653, 2006.
94. Karin M, Yamamoto Y, and Wang QM: The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3, 17-26, 2004.
95. Kim HJ, Hawke N, and Baldwin AS: NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ 13, 738-747, 2006.
96. Allen CT, Ricker JL, Chen Z, and Van Waes C: Role of activated nuclear factor-kappaB inthe pathogenesis and therapy ofsquamous cell carcinoma of the head and neck. Head Neck 29, 959-971, 2007.
97. Dudek AZ, Lesniewski-Kmak K, Shehadeh NJ, Pandey ON, Franklin M, et al.: Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor. Br J Cancer 100, 1379-1384, 2009.
98. Karin M: The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270, 16483-16486, 1995.
99. Shaulian E and Karin M: AP-1 in cell proliferation and survival. Oncogene 20, 2390-2400, 2001.
100. Chen Z, Ricker JL, Malhotra PS, Nottingham L, Bagain L, et al.: Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms. Mol Cancer Ther 7, 1949-1960, 2008.
101. Zeng Q, McCauley LK, and Wang CY: Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J Biol Chem 277, 50137-50142, 2002. (Pubitemid 36014467)
102. Lin F, Xiao D, Kolluri SK, and Zhang X: Unique anti-activator protein-1 activity of retinoic acid receptor beta. Cancer Res 60, 3271-3280, 2000.
103. Huang C, Ma WY, Dawson MI, Rincon M, Flavell RA, et al.: Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci USA 94, 5826-5830, 1997.
104. Leaman DW, Leung S, Li X, and Stark GR: Regulationof STAT-dependent pathways by growth factors and cytokines. FASEB J 10, 1578-1588, 1996.
105. Liu KD, Gaffen SL, and Goldsmith MA: JAK/STAT signaling by cytokine receptors. Curr Opin Immunol 10, 271-278, 1998.
106. Leonard WJ and O'Shea JJ: Jaks and STATs: biological implications. Annu Rev Immunol 16, 293-322, 1998.
107. Bowman T, Garcia R, Turkson J, and Jove R: STATs in oncogenesis. Oncogene 19, 2474-2488, 2000.
108. Song JI and Grandis JR: STAT signaling in head and neck cancer. Oncogene 19, 2489-2495, 2000.
109. Masuda M, Suzui M, Yasumatu R, Nakashima T, Kuratomi Y, et al.: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62, 3351-3355, 2002.
110. Xi S, Zhang Q, Dyer KF, Lerner EC, Smithgall TE, et al.: Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 278, 31574-31583, 2003.
111. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, et al.: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest 102, 1385-1392, 1998.
112. Benekli M, Baer MR, Baumann H, and Wetzler M: Signal transducer and activator of transcription proteins in leukemias. Blood 101, 2940-2954, 2003.
113. LoPiccolo J, Blumenthal GM, Bernstein WB, and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11, 32-50, 2008.
114. Moral M and Paramio JM: Akt pathway as a target for therapeutic intervention in HNSCC. Histol Histopathol 23, 1269-1278, 2008.
115. Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, et al.: Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 10, 4029-4037, 2004.
116. Bussink J, Van der Kogel AJ, and Kaanders JH: Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 9, 288-296, 2008.
117. Liu FY, Zhao ZJ, Li P, Ding X, Zong ZH, et al.: Mammalian target of rapamycin (mTOR) is involved in the survival of cells mediated by chemokine receptor 7 through PI3K/Akt in metastatic squamous cell carcinoma of the head and neck. Br J Oral Maxillofac Surg 48, 291-296, 2010.
118. Shang ZJ, Li ZB, and Li JR: VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies. Int J Oral Maxillofac Surg 35, 533-538, 2006.
119. Liang X, Yang D, Hu J, Hao X, Gao J, et al.: Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma. Anticancer Res 28, 1659-1666, 2008.
120. Beeram M, Patnaik A, and Rowinsky EK: Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 23, 6771-6790, 2005.
121. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438, 967-974, 2005.
122. Elser C, Siu LL, Winquist E, Agulnik M, Pond GR, et al.: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25, 3766-3773, 2007.
123. Cushnie TP and Lamb AJ: Antimicrobial activity of flavonoids. Int J Antimicrob Agents 26, 343-356, 2005.
124. Petti S and Scully C: Polyphenols, oral health and disease: a review. J Dent 37, 413-423, 2009.
125. Halliwell B, Zhao K, and Whiteman M: The gastrointestinal tract: a major site of antioxidant action? Free Radic Res 33, 819-830, 2000.
126. Walle T, Browning AM, Steed LL, Reed SG, and Walle UK: Flavonoid glucosides are hydrolyzed and thus activated in the oral cavity in humans. J Nutr 135, 48-52, 2005.
127. Bode AM and Dong Z: Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail. Cancer Prev Res (Phila Pa) 2, 514-517, 2009.
128. Cao Y and Cao R: Angiogenesis inhibited by drinking tea. Nature 398, 381, 1999.
129. Beltz LA, Bayer DK, Moss AL, and Simet IM: Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med Chem 6, 389-406, 2006.
130. Khan N, Afaq F, and Mukhtar H: Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10, 475-510, 2008.
131. Yang CS, Maliakal P, and Meng X: Inhibition of carcinogenesis by tea. Annu Rev Pharmacol Toxicol 42, 25-54, 2002.
132. Suganuma M, Sueoka E, Sueoka N, Okabe S, and Fujiki H: Mechanisms of cancer prevention by tea polyphenols based on inhibition of TNF-alpha expression. Biofactors 13, 67-72, 2000.
133. Shin DM: Oral cancer prevention advances with a translational trial of green tea. Cancer Prev Res (Phila Pa) 2, 919-921, 2009.
134. Ahmad N, Cheng P, and Mukhtar H: Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem Biophys Res Commun 275, 328-334, 2000.
135. Khafif A, Schantz SP, al-Rawi M, Edelstein D, and Sacks PG: Green tea regulates cell cycle progression in oral leukoplakia. Head Neck 20, 528-534, 1998.
136. Hastak K, Agarwal MK, Mukhtar H, and Agarwal ML: Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 19, 789-791, 2005.
137. Nihal M, Ahsan H, Siddiqui IA, Mukhtar H, Ahmad N, et al.: (-) - Epigallocatechin-3-gallate (EGCG) sensitizes melanoma cells to interferon induced growth inhibition in a mouse model of human melanoma. Cell Cycle 8, 2057-2063, 2009.
138. Lamy S, Gingras D, and Beliveau R: Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res 62, 381-385, 2002.
139. Masuda M, Suzui M, Lim JT, Deguchi A, Soh JW, et al.: Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2, 350-359, 2002.
140. Kim HS, Kim MH, Jeong M, Hwang YS, Lim SH, et al.: EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res 24, 747-753, 2004.
141. Fujiki H, Yoshizawa S, Horiuchi T, Suganuma M, Yatsunami J, et al.: Anticarcinogenic effects of (-)-epigallocatechin gallate. Prev Med 21, 503-509, 1992.
142. Fujiki H, Suganuma M, Okabe S, Sueoka E, Suga K, et al.: Mechanistic findings of green tea as cancer preventive for humans. Proc Soc Exp Biol Med 220, 225-228, 1999.
143. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, et al.: Phase I trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 19, 1830-1838, 2001.
144. Seeram NP, Adams LS, Henning SM, Niu Y, Zhang Y, et al.: In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem 16, 360-367, 2005.
145. Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, et al.: Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res 69, 1712-1716, 2009.
146. Kuttan R, Bhanumathy P, Nirmala K, and George MC: Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 29, 197-202, 1985.
147. Kuttan R, Sudheeran PC, and Josph CD: Turmeric and curcumin as topical agents in cancer therapy. Tumori 73, 29-31, 1987.
148. Kasinski AL, Du Y, Thomas SL, Zhao J, Sun SY, et al.: Inhibition of IkappaB kinase-nuclear factor-kappaB signaling pathway by 3, 5-bis (2-flurobenzylidene) piperidin-4-one (EF24), a novel monoketone analog of curcumin. Mol Pharmacol 74, 654-661, 2008.
149. Bar-Sela G, Epelbaum R, and Schaffer M: Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 17, 190-197, 2010.
150. Thangapazham RL, Sharma A, and Maheshwari RK: Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J 8, E443-449, 2006.
151. Conney AH: Enzyme induction and dietary chemicals as approaches to cancer chemoprevention: the Seventh DeWitt S. Goodman Lecture. Cancer Res 63, 7005-7031, 2003.
152. Li N, Chen X, Liao J, Yang G, Wang S, et al.: Inhibition of 7, 12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamsters by tea and curcumin. Carcinogenesis 23, 1307-1313, 2002.
153. Goel A, Jhurani S, and Aggarwal BB: Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res 52, 1010-1030, 2008.
154. Aggarwal S, Takada Y, Singh S, Myers JN, and Aggarwal BB: Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 111, 679-692, 2004.
155. Goel A, Boland CR, and Chauhan DP: Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 172, 111-118, 2001.
156. John A and Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 7, 14-23, 2001.
157. Woo MS, Jung SH, Kim SY, Hyun JW, Ko KH, et al.: Curcumin suppresses phorbol ester-induced matrix metalloproteinase-9 expression by inhibiting the PKC to MAPK signaling pathways in human astroglioma cells. Biochem Biophys Res Commun 335, 1017-1025, 2005.
158. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21, 2895-2900, 2001.
159. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, et al.: Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 7, 1894-1900, 2001.
160. Verma SP, Salamone E, and Goldin B: Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. Biochem Biophys Res Commun 233, 692-696, 1997.
161. Khafif A, Schantz SP, Chou TC, Edelstein D, and Sacks PG: Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis 19, 419-424, 1998.
162. Koo JY, Kim HJ, Jung KO, and Park KY: Curcumin inhibits the growth of AGS human gastric carcinoma cells in vitro and shows synergism with 5-fluorouracil. J Med Food 7, 117-121, 2004.
163. Sen S, Sharma H, and Singh N: Curcumin enhances Vinorelbine mediated apoptosisin NSCLC cellsbythe mitochondrial pathway. Biochem Biophys Res Commun 331, 1245-1252, 2005.
164. Cruz-Correa M, Shoskes DA, Sanchez P, Zhao R, Hylind LM, et al.: Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clin Gastroenterol Hepatol 4, 1035-1038, 2006.
165. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, et al.: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64, 353-356, 1998.
166. Adams BK, Ferstl EM, Davis MC, Herold M, Kurtkaya S, et al.: Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents. Bioorg Med Chem 12, 3871-3883, 2004.
167. Adams BK, Cai J, Armstrong J, Herold M, Lu YJ, et al.: EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redoxdependent mechanism. Anticancer Drugs 16, 263-275, 2005.
168. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, et al.: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220, 1997.
169. Baur JA and Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5, 493-506, 2006.
170. Garvin S, Ollinger K, and Dabrosin C: Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett 231, 113-122, 2006.
171. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, and Watson RW: Resveratrol sensitizes androgen independent prostate cancer cells to deathreceptor mediated apoptosis through multiple mechanisms. Prostate 67, 1641-1653, 2007.
172. Aziz MH, Nihal M, Fu VX, Jarrard DF, and Ahmad N: Resveratrolcaused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol Cancer Ther 5, 1335-1341, 2006.
173. Ma X, Tian X, Huang X, Yan F, and Qiao D: Resveratrol-induced mitochondrial dysfunction and apoptosis are associated with Ca2+ and mCICR-mediated MPT activation in HepG2 cells. Mol Cell Biochem 302, 99-109, 2007.
174. Cao Y, Fu ZD, Wang F, Liu HY, and Han R: Anti-angiogenic activity of resveratrol, a natural compound from medicinal plants. J Asian Nat Prod Res 7, 205-213, 2005.
175. Gao X, Xu YX, Divine G, Janakiraman N, Chapman RA, et al.: Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. J Nutr 132, 2076-2081, 2002.
176. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, et al.: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224, 274-283, 2007.
177. Kimura Y and Okuda H: Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 131, 1844-1849, 2001.
178. Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A, et al.: Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis 23, 1531-1536, 2002.
179. Niles RM, Cook CP, Meadows GG, Fu YM, McLaughlin JL, et al.: Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr 136, 2542-2546, 2006.
180. Teskac K and Kristl J: The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 390, 61-69, 2010.
181. Giovannucci E: Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst 91, 317-331, 1999.
182. Seren S, Lieberman R, Bayraktar UD, Heath E, Sahin K, et al.: Lycopene in cancer prevention and treatment. Am J Ther 15, 66-81, 2008.
183. Franceschi S, Bidoli E, La Vecchia C, Talamini R, D'Avanzo B, et al.: Tomatoes and risk of digestive-tract cancers. Int J Cancer 59, 181-184, 1994.
184. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, and Willett WC: A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst 94, 391-398, 2002.
185. Wang AH and Zhang LS: [Effect of lycopene on the proliferation of MCF-7 and MDA-MB-231 cells]. Sichuan Da Xue Xue Bao Yi Xue Ban 38, 958-960, 976, 2007.
186. Fornelli F, Leone A, Verdesca I, Minervini F, and Zacheo G: The influence of lycopene on the proliferationof human breast cell line (MCF-7). Toxicol In Vitro 21, 217-223, 2007.
187. Narisawa T, Fukaura Y, Hasebe M, Ito M, Aizawa R, et al.: Inhibitory effects of natural carotenoids, alpha-carotene, beta-carotene, lycopene and lutein, on colonic aberrant crypt foci formation in rats. Cancer Lett 107, 137-142, 1996.
188. Conn PF, Schalch W, and Truscott TG: The singlet oxygen and carotenoid interaction. J Photochem Photobiol B 11, 41-47, 1991.
189. Amir H, Karas M, Giat J, Danilenko M, Levy R, et al.: Lycopene and 1, 25-dihydroxyvitamin D3 cooperate in the inhibition of cell cycle progression and induction of differentiation in HL-60 leukemic cells. Nutr Cancer 33, 105-112, 1999.
190. Karas M, Amir H, Fishman D, Danilenko M, Segal S, et al.: Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 36, 101-111, 2000.
191. Schwarz S, Obermuller-Jevic UC, Hellmis E, Koch W, Jacobi G, et al.: Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 138, 49-53, 2008.
192. Kim HS, Bowen P, Chen L, Duncan C, Ghosh L, et al.: Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr Cancer 47, 40-47, 2003.
193. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, et al.: Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10, 861-868, 2001.
194. Vaishampayan U, Hussain M, Banerjee M, Seren S, Sarkar FH, et al.: Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer 59, 1-7, 2007.
195. Miean KH and Mohamed S: Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agric Food Chem 49, 3106-3112, 2001.
196. Shimoi K, Saka N, Kaji K, Nozawa R, and Kinae N: Metabolic fate of luteolin and its functional activity at focal site. Biofactors 12, 181-186, 2000.
197. Yang SF, Yang WE, Chang HR, Chu SC, and Hsieh YS: Luteolin induces apoptosis in oral squamous cancer cells. J Dent Res 87, 401-406, 2008.
198. Ueda H, Yamazaki C, and Yamazaki M: Inhibitory effect of Perilla leaf extract and luteolin on mouse skin tumor promotion. Biol Pharm Bull 26, 560-563, 2003.
199. Zhang Q, Zhao XH, and Wang ZJ: Flavones and flavonols exert cytotoxic effects on a human oesophageal adenocarcinoma cell line (OE33) by causing G2/M arrest and inducing apoptosis. Food Chem Toxicol 46, 2042-2053, 2008.
200. Ju W, Wang X, Shi H, Chen W, Belinsky SA, et al.: A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol 71, 1381-1388, 2007.
201. Limdo Y, Jeong Y, Tyner AL, and Park JH: Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol 292, G66-75, 2007.
202. Selvendiran K, Koga H, Ueno T, Yoshida T, Maeyama M, et al.: Luteolin promotes degradation in signal transducer and activator of transcription 3 in human hepatoma cells: an implication for the antitumor potential of flavonoids. Cancer Res 66, 4826-4834, 2006.
203. Chiang CT, Way TD, and Lin JK: Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21 (WAF1/CIP1) expression with rapamycin. Mol Cancer Ther 6, 2127-2138, 2007.
204. Zhou Q, Yan B, Hu X, Li XB, Zhang J, et al.: Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther 8, 1684-1691, 2009.
205. Kim ND, Mehta R, Yu W, Neeman I, Livney T, et al.: Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 71, 203-217, 2002.
206. Zhang Y, Vareed SK, and Nair MG: Human tumor cell growth inhibition by nontoxic anthocyanidins, the pigments in fruits and vegetables. Life Sci 76, 1465-1472, 2005.
207. Malik A, Afaq F, Sarfaraz S, Adhami VM, Syed DN, et al.: Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 102, 14813-14818, 2005.
208. Hora JJ, Maydew ER, Lansky EP, and Dwivedi C: Chemopreventive effects of pomegranate seed oil on skin tumor development in CD1 mice. J Med Food 6, 157-161, 2003. (Pubitemid 37445026)
209. Sartippour MR, Seeram NP, Rao JY, Moro A, Harris DM, et al.: Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol 32, 475-480, 2008.
210. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, et al.: Nutritional and socioeconomic factors in relation to prostate cancer mortality: a crossnational study. J Natl Cancer Inst 90, 1637-1647, 1998.
211. Ziegler RG, Hoover RN, Pike MC, Hildesheim A, Nomura AM, et al.: Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst 85, 1819-1827, 1993.
212. Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, et al.: Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 146, 294-306, 1997.
213. Jurenka JS: Therapeutic applications of pomegranate (Punica granatum L.): a review. Altern Med Rev 13, 128-144, 2008.
214. Heber D: Multitargeted therapy of cancer by ellagitannins. Cancer Lett 269, 262-268, 2008.